Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells

Cell Reports

Volumn 16, Issue 2, 2016, Pages 457-471

  Forloni, Matteo ^a   Gupta, Romi ^a   Nagarajan, Arvindhan ^a   Sun, Li Sha ^a   Dong, Yuying ^a   Pirazzoli, Valentina ^b   Toki, Maria ^a   Wurtz, Anna ^b   Melnick, Mary Ann ^b   Kobayashi, Susumu ^c   Homer, Robert J ^a,b   Rimm, David L ^a,b   Gettinger, Scott J ^a,b   Politi, Katerina ^a,b   Dogra, Shaillay Kumar ^d   Wajapeyee, Narendra ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DECITABINE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RNA POLYMERASE II; RUXOLITINIB; TET ONCOGENE FAMILY MEMBER 1 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; WORTMANNIN; ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; PROTEIN KINASE INHIBITOR; TET1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TET1 GENE; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CPG ISLAND; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; MAPK SIGNALING; METABOLISM; MUTATION; ONCOGENE; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLIOBLASTOMA; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MIXED FUNCTION OXYGENASES; MUTATION; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84992494145     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.05.087     Document Type: Article

References (31)

1. Baylin, S.B., Jones, P.A., A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11 (2011), 726–734.
2. Baylin, S.B., Ohm, J.E., Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006), 107–116.
3. Cimmino, L., Dawlaty, M.M., Ndiaye-Lobry, D., Yap, Y.S., Bakogianni, S., Yu, Y., Bhattacharyya, S., Shaknovich, R., Geng, H., Lobry, C., et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16 (2015), 653–662.
4. Costa, D.B., Halmos, B., Kumar, A., Schumer, S.T., Huberman, M.S., Boggon, T.J., Tenen, D.G., Kobayashi, S., BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4 (2007), 1669–1679 discussion 1680.
5. Foley, J., Nickerson, N.K., Nam, S., Allen, K.T., Gilmore, J.L., Nephew, K.P., Riese, D.J. 2nd, EGFR signaling in breast cancer: bad to the bone. Semin. Cell Dev. Biol. 21 (2010), 951–960.
6. Fu, H.L., Ma, Y., Lu, L.G., Hou, P., Li, B.J., Jin, W.L., Cui, D.X., TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J. Biomed. Nanotechnol. 10 (2014), 1217–1230.
7. Furnari, F.B., Cloughesy, T.F., Cavenee, W.K., Mischel, P.S., Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 15 (2015), 302–310.
8. Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C.M., Green, M.R., An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449 (2007), 1073–1077.
9. Gordon, S., Akopyan, G., Garban, H., Bonavida, B., Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 25 (2006), 1125–1142.
10. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N. Engl. J. Med. 359 (2008), 1367–1380.
11. Huang, P.H., Xu, A.M., White, F.M., Oncogenic EGFR signaling networks in glioma. Sci. Signal., 2, 2009, re6.
12. Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M.N., Hedlund, E.K., Rusch, M.C., et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat. Commun., 5, 2014, 3630.
13. Kobayashi, S., Shimamura, T., Monti, S., Steidl, U., Hetherington, C.J., Lowell, A.M., Golub, T., Meyerson, M., Tenen, D.G., Shapiro, G.I., Halmos, B., Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 66 (2006), 11389–11398.
14. Kohli, R.M., Zhang, Y., TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502 (2013), 472–479.
15. Lu, H.G., Zhan, W., Yan, L., Qin, R.Y., Yan, Y.P., Yang, Z.J., Liu, G.C., Li, G.Q., Wang, H.F., Li, X.L., et al. TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol. Med. Rep. 10 (2014), 2595–2600.
16. Lurje, G., Lenz, H.J., EGFR signaling and drug discovery. Oncology 77 (2009), 400–410.
17. Neri, F., Dettori, D., Incarnato, D., Krepelova, A., Rapelli, S., Maldotti, M., Parlato, C., Paliogiannis, P., Oliviero, S., TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 34 (2015), 4168–4176.
18. Palakurthy, R.K., Wajapeyee, N., Santra, M.K., Gazin, C., Lin, L., Gobeil, S., Green, M.R., Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol. Cell 36 (2009), 219–230.
19. Pastor, W.A., Aravind, L., Rao, A., TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14 (2013), 341–356.
20. Pirazzoli, V., Ayeni, D., Meador, C.B., Sanganahalli, B., Hyder, F., de Stanchina, E., Goldberg, S.B., Pao, W., Politi, K., Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 426–435.
21. Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W., Varmus, H.E., Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20 (2006), 1496–1510.
22. Politi, K., Ayeni, D., Lynch, T., The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell 27 (2015), 751–753.
23. Serra, R.W., Fang, M., Park, S.M., Hutchinson, L., Green, M.R., A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. eLife, 3, 2014, e02313.
24. Sheng, Q., Liu, J., The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 104 (2011), 1241–1245.
25. Stoeckius, M., Erat, A., Fujikawa, T., Hiromura, M., Koulova, A., Otterbein, L., Bianchi, C., Tobiasch, E., Dagon, Y., Sellke, F.W., Usheva, A., Essential roles of Raf/extracellular signal-regulated kinase/mitogen-activated protein kinase pathway, YY1, and Ca2+ influx in growth arrest of human vascular smooth muscle cells by bilirubin. J. Biol. Chem. 287 (2012), 15418–15426.
26. Sun, M., Song, C.X., Huang, H., Frankenberger, C.A., Sankarasharma, D., Gomes, S., Chen, P., Chen, J., Chada, K.K., He, C., Rosner, M.R., HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl. Acad. Sci. USA 110 (2013), 9920–9925.
27. Traish, A.M., Morgentaler, A., Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br. J. Cancer 101 (2009), 1949–1956.
28. Troiani, T., Martinelli, E., Capasso, A., Morgillo, F., Orditura, M., De Vita, F., Ciardiello, F., Targeting EGFR in pancreatic cancer treatment. Curr. Drug Targets 13 (2012), 802–810.
29. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
30. Wajapeyee, N., Malonia, S.K., Palakurthy, R.K., Green, M.R., Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 27 (2013), 2221–2226.
31. Yang, L., Yu, S.J., Hong, Q., Yang, Y., Shao, Z.M., Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer. PLoS ONE, 10, 2015, e0133896.